Purpose The purpose of the study was the identification of group and individual subject patterns of cerebral glucose metabolism (CMRGlu) in patients with Alzheimer’s disease (AD) and with amnestic mild cognitive impairment (aMCI). Methods [18F]fluorodeoxyglucose positron emission tomography (PET) studies and neuropsychological tests were performed in 16 aMCI patients (ten women, age 75 ± 8 years) and in 14 AD patients (ten women, age 75 ± 9 years). Comparisons between patient subgroups and with a control population were performed using Statistical Parametric Mapping. Results Clusters of low CMRGlu were observed bilaterally in the posterior cingulate cortex (PCC), in the precuneus, in the inferior parietal lobule and middle temp...
This study investigated cerebral glucose metabolism in very early Alzheimer's disease, before a clin...
OBJECTIVE: A subgroup of patients with Alzheimer's disease present with visual disturbances at onset...
OBJECTIVE: A subgroup of patients with Alzheimer's disease present with visual disturbances at onset...
Background: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...
Background: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...
BACKGROUND: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...
Objective: It is well established that regional cerebral metabolic rates for glucose assessed by 18F...
A pattern of reduced cerebral metabolic rate for glucose (rCMRglc) has been shown by positron emissi...
A pattern of reduced cerebral metabolic rate for glucose (rCMRglc) has been shown by positron emissi...
Using [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) patients with Alzheimer's di...
Using [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) patients with Alzheimer's di...
Purpose: [F-18] fluorodeoxyglucose (FDG) PET imaging of the brain can be used to assist in the diffe...
Purpose: [F-18] fluorodeoxyglucose (FDG) PET imaging of the brain can be used to assist in the diffe...
Abstract Brain 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been utilized to mo...
Thirty‐eight patients with mild to moderate Alzheimer's disease (AD) underwent a neuropsychological ...
This study investigated cerebral glucose metabolism in very early Alzheimer's disease, before a clin...
OBJECTIVE: A subgroup of patients with Alzheimer's disease present with visual disturbances at onset...
OBJECTIVE: A subgroup of patients with Alzheimer's disease present with visual disturbances at onset...
Background: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...
Background: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...
BACKGROUND: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk...
Objective: It is well established that regional cerebral metabolic rates for glucose assessed by 18F...
A pattern of reduced cerebral metabolic rate for glucose (rCMRglc) has been shown by positron emissi...
A pattern of reduced cerebral metabolic rate for glucose (rCMRglc) has been shown by positron emissi...
Using [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) patients with Alzheimer's di...
Using [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) patients with Alzheimer's di...
Purpose: [F-18] fluorodeoxyglucose (FDG) PET imaging of the brain can be used to assist in the diffe...
Purpose: [F-18] fluorodeoxyglucose (FDG) PET imaging of the brain can be used to assist in the diffe...
Abstract Brain 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) has been utilized to mo...
Thirty‐eight patients with mild to moderate Alzheimer's disease (AD) underwent a neuropsychological ...
This study investigated cerebral glucose metabolism in very early Alzheimer's disease, before a clin...
OBJECTIVE: A subgroup of patients with Alzheimer's disease present with visual disturbances at onset...
OBJECTIVE: A subgroup of patients with Alzheimer's disease present with visual disturbances at onset...